2020
Commensal Microbiota Modulation of Natural Resistance to Virus Infection
Stefan KL, Kim MV, Iwasaki A, Kasper DL. Commensal Microbiota Modulation of Natural Resistance to Virus Infection. Cell 2020, 183: 1312-1324.e10. PMID: 33212011, PMCID: PMC7799371, DOI: 10.1016/j.cell.2020.10.047.Peer-Reviewed Original ResearchConceptsMicrobial moleculesVesicular stomatitis virusCommensal microbesSpecific commensal microbesInduction of IFNVirus infectionNatural resistanceOuter membraneGut commensal microbesIFN-β expressionImmune system regulationHuman diseasesPhysiological importanceInduces expressionSource of IFNMicrobesHomeostatic conditionsStomatitis virusIFN-IsMicrobiota modulationAntiviral immunityCrucial mediatorIFNPolysaccharide AAntiviral activityLassa-VSV chimeric virus targets and destroys human and mouse ovarian cancer by direct oncolytic action and by initiating an anti-tumor response
van den Pol A, Zhang X, Lima E, Pitruzzello M, Albayrak N, Alvero A, Davis J, Mor G. Lassa-VSV chimeric virus targets and destroys human and mouse ovarian cancer by direct oncolytic action and by initiating an anti-tumor response. Virology 2020, 555: 44-55. PMID: 33453650, PMCID: PMC8451984, DOI: 10.1016/j.virol.2020.10.009.Peer-Reviewed Original ResearchConceptsOvarian cancer cellsHuman ovarian cancer cellsLong-term survivalOvarian cancerCancer cellsTreatment of immunocompetent miceKill ovarian cancer cellsMouse ovarian cancer cellsTreatment of ovarian cancerAnti-tumor responsesImmunocompromised nude miceOncolytic actionImmunocompetent miceMetastatic spreadChemotherapeutic paclitaxelFemale cancersPoor survivalNude miceIntraperitoneal injectionCancer growthSurvival extensionVesicular stomatitis virusVSV glycoproteinCancerReduced neurotropismGenome-wide CRISPR Screens Reveal Host Factors Critical for SARS-CoV-2 Infection
Wei J, Alfajaro MM, DeWeirdt PC, Hanna RE, Lu-Culligan WJ, Cai WL, Strine MS, Zhang SM, Graziano VR, Schmitz CO, Chen JS, Mankowski MC, Filler RB, Ravindra NG, Gasque V, de Miguel FJ, Patil A, Chen H, Oguntuyo KY, Abriola L, Surovtseva YV, Orchard RC, Lee B, Lindenbach BD, Politi K, van Dijk D, Kadoch C, Simon MD, Yan Q, Doench JG, Wilen CB. Genome-wide CRISPR Screens Reveal Host Factors Critical for SARS-CoV-2 Infection. Cell 2020, 184: 76-91.e13. PMID: 33147444, PMCID: PMC7574718, DOI: 10.1016/j.cell.2020.10.028.Peer-Reviewed Original ResearchMeSH KeywordsAngiotensin-Converting Enzyme 2AnimalsCell LineChlorocebus aethiopsClustered Regularly Interspaced Short Palindromic RepeatsCoronavirusCoronavirus InfectionsCOVID-19Gene Knockout TechniquesGene Regulatory NetworksGenome-Wide Association StudyHEK293 CellsHMGB1 ProteinHost-Pathogen InteractionsHumansSARS-CoV-2Vero CellsVirus InternalizationConceptsSARS-CoV-2 infectionSARS-CoV-2Vesicular stomatitis virusGenome-wide CRISPR screenSWI/SNF chromatinSARS-CoV-2 host factorsAcute respiratory syndrome coronavirus 2 infectionSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infectionTherapeutic targetHost factorsCoronavirus disease 2019 (COVID-19) pathogenesisSyndrome coronavirus 2 infectionCRISPR screensHost genesGene productsMiddle East respiratory syndrome CoVCoronavirus 2 infectionGenetic hitsHuman cellsSARS-CoV-2 spikeNovel therapeutic targetPotential therapeutic targetVero E6 cellsSARS-CoV-1Small molecule antagonistsModified Alphavirus-Vesiculovirus Hybrid Vaccine Vectors for Homologous Prime-Boost Immunotherapy of Chronic Hepatitis B
Chiale C, Yarovinsky TO, Mason SW, Madina BR, Menon M, Krady MM, Moshkani S, Pal A, Almassian B, Rose JK, Robek MD, Nakaar V. Modified Alphavirus-Vesiculovirus Hybrid Vaccine Vectors for Homologous Prime-Boost Immunotherapy of Chronic Hepatitis B. Vaccines 2020, 8: 279. PMID: 32517032, PMCID: PMC7349932, DOI: 10.3390/vaccines8020279.Peer-Reviewed Original ResearchMucin-Like Domain of Ebola Virus Glycoprotein Enhances Selective Oncolytic Actions against Brain Tumors
Zhang X, Zhang T, Davis JN, Marzi A, Marchese AM, Robek MD, van den Pol AN. Mucin-Like Domain of Ebola Virus Glycoprotein Enhances Selective Oncolytic Actions against Brain Tumors. Journal Of Virology 2020, 94: 10.1128/jvi.01967-19. PMID: 32051271, PMCID: PMC7108827, DOI: 10.1128/jvi.01967-19.Peer-Reviewed Original ResearchConceptsChimeric vesicular stomatitis virusVSV-EBOVNormal brain cellsBrain tumorsVesicular stomatitis virusEBOV glycoproteinEbola virus glycoproteinEbola virusBrain cellsNormal immunocompetent miceBrain tumor-bearing miceImmunodeficient SCID miceTumor-bearing miceHuman brain tumorsSCID mouse brainStomatitis virusTranscription-quantitative PCRMost tumor cellsVirus glycoproteinOncolytic actionImmune system evasionImmunocompetent miceWild-type vesicular stomatitis virusSCID miceVirus infection
2018
A recombinant virus vaccine that protects against both Chikungunya and Zika virus infections
Chattopadhyay A, Aguilar PV, Bopp NE, Yarovinsky TO, Weaver SC, Rose JK. A recombinant virus vaccine that protects against both Chikungunya and Zika virus infections. Vaccine 2018, 36: 3894-3900. PMID: 29807712, DOI: 10.1016/j.vaccine.2018.05.095.Peer-Reviewed Original ResearchConceptsChikungunya virusZika virusA129 miceVesicular stomatitis virusChimeric vesicular stomatitis virusZika virus infectionWild-type miceSingle-dose vaccineRecombinant virus vaccineCo-circulating virusesLicensed vaccineSingle vaccinationZIKV infectionAntibody responsePandemic proportionsVirus vaccineVirus infectionAnimal modelsExperimental vaccinesVaccineMiceInfectionInvasive mosquito vectorsVSV glycoproteinVirus
2017
Sophoraflavenone G Restricts Dengue and Zika Virus Infection via RNA Polymerase Interference
Sze A, Olagnier D, Hadj SB, Han X, Tian XH, Xu HT, Yang L, Shi Q, Wang P, Wainberg MA, Wu JH, Lin R. Sophoraflavenone G Restricts Dengue and Zika Virus Infection via RNA Polymerase Interference. Viruses 2017, 9: 287. PMID: 28972551, PMCID: PMC5691638, DOI: 10.3390/v9100287.Peer-Reviewed Original ResearchConceptsZika virus infectionHepatitis C virusHepatitis C replicationPost-infection treatmentGlobal health concernAntiviral treatmentC virusVirus infectionVesicular stomatitis virusZika virusAntiviral compoundsHealth concernChinese medicinePolymerase inhibitionDengueStomatitis virusVirusTreatmentRNA polymerase inhibitionInfectionDiseaseFlavivirusesChikungunya, Influenza, Nipah, and Semliki Forest Chimeric Viruses with Vesicular Stomatitis Virus: Actions in the Brain
van den Pol AN, Mao G, Chattopadhyay A, Rose JK, Davis JN. Chikungunya, Influenza, Nipah, and Semliki Forest Chimeric Viruses with Vesicular Stomatitis Virus: Actions in the Brain. Journal Of Virology 2017, 91: 10.1128/jvi.02154-16. PMID: 28077641, PMCID: PMC5331823, DOI: 10.1128/jvi.02154-16.Peer-Reviewed Original ResearchConceptsAdult mouse brainVesicular stomatitis virusVSV glycoprotein (G) geneAdult brainChimeric virusesOncolytic virusesVirus-like vesiclesChimeric vesicular stomatitis virusMouse brainSemliki Forest virusStomatitis virusPostnatal day 14 miceHealthy adult mouse brainRecombinant vesicular stomatitis virusKey immune mechanismsType I interferon responseG glycoproteinI interferon responseInterferon-stimulated genesDay 14 miceInfluenza H5N1 virusGlycoprotein geneNeurotropic natureIntranasal inoculationWild-type vesicular stomatitis virus
2015
Lassa-Vesicular Stomatitis Chimeric Virus Safely Destroys Brain Tumors
Wollmann G, Drokhlyansky E, Davis JN, Cepko C, van den Pol AN. Lassa-Vesicular Stomatitis Chimeric Virus Safely Destroys Brain Tumors. Journal Of Virology 2015, 89: 6711-6724. PMID: 25878115, PMCID: PMC4468483, DOI: 10.1128/jvi.00709-15.Peer-Reviewed Original ResearchConceptsLymphocytic choriomeningitis virusBrain tumorsVesicular stomatitis virusChimeric virusesBrain cancerLassa virusEbola virusMarburg virusRabies virusAdverse neurologic consequencesExquisite tumor specificityHigh-grade tumorsPromising oncolytic virusLassa virus glycoprotein precursorAdverse side effectsTumor-bearing miceMetastatic cancer modelsStomatitis virusNovel chimeric virusHigh-grade glioblastomaEbola virus glycoproteinMultiple cancer typesNoninjected tumorNeurologic consequencesOncolytic potential
2013
Single-dose replication-defective VSV-based Nipah virus vaccines provide protection from lethal challenge in Syrian hamsters
Lo MK, Bird BH, Chattopadhyay A, Drew CP, Martin BE, Coleman JD, Rose JK, Nichol ST, Spiropoulou CF. Single-dose replication-defective VSV-based Nipah virus vaccines provide protection from lethal challenge in Syrian hamsters. Antiviral Research 2013, 101: 26-29. PMID: 24184127, PMCID: PMC3874889, DOI: 10.1016/j.antiviral.2013.10.012.Peer-Reviewed Original ResearchConceptsFatal human encephalitisSingle-dose protectionReplication-defective vesicular stomatitis virusSafety profileLethal challengeSingle doseVirus vaccineEnhanced safety profileHuman encephalitisVaccine vectorVesicular stomatitis virusSyrian hamstersNiV fusionNipah virusBat reservoirsStomatitis virusAttachment glycoproteinHamstersVirusEncephalitisVaccineDoseVesicular Stomatitis Virus Variants Selectively Infect and Kill Human Melanomas but Not Normal Melanocytes
Wollmann G, Davis JN, Bosenberg MW, van den Pol AN. Vesicular Stomatitis Virus Variants Selectively Infect and Kill Human Melanomas but Not Normal Melanocytes. Journal Of Virology 2013, 87: 6644-6659. PMID: 23552414, PMCID: PMC3676084, DOI: 10.1128/jvi.03311-12.Peer-Reviewed Original ResearchConceptsVesicular stomatitis virusReplication-competent vesicular stomatitis virusMetastatic malignant melanomaRecombinant vesicular stomatitis virusMouse melanoma modelHuman melanoma samplesGene mutation statusVSV-CT9Low viral concentrationsMelanoma typesMalignant melanomaSCID miceViral oncolysisMelanoma xenograftsViral infectionMelanoma modelMutation statusMalignant transformationHuman melanomaInfectionMelanomaVirus variantsComplete protectionMelanoma samplesGene mutationsSTOCHASTIC TEMPERATURES IMPEDE RNA VIRUS ADAPTATION
Alto BW, Wasik BR, Morales NM, Turner PE. STOCHASTIC TEMPERATURES IMPEDE RNA VIRUS ADAPTATION. Evolution 2013, 67: 969-979. PMID: 23550749, DOI: 10.1111/evo.12034.Peer-Reviewed Original ResearchConceptsFitness gainsVesicular stomatitis virusEvolution of generalistsConvergent molecular evolutionEvolution of specializationCell-binding proteinsMolecular evolutionGenome substitutionsConstant environmentVirus adaptationSequence analysisRNA virusesG geneVirus populationsStomatitis virusMolecular changesLineagesGeneralistsTemperature treatmentKey roleEvolutionGenesLociVirusProteinTranssynaptic Tracing with Vesicular Stomatitis Virus Reveals Novel Retinal Circuitry
Beier KT, Borghuis BG, El-Danaf RN, Huberman AD, Demb JB, Cepko CL. Transsynaptic Tracing with Vesicular Stomatitis Virus Reveals Novel Retinal Circuitry. Journal Of Neuroscience 2013, 33: 35-51. PMID: 23283320, PMCID: PMC3711516, DOI: 10.1523/jneurosci.0245-12.2013.Peer-Reviewed Original ResearchConceptsStarburst amacrine cellsVesicular stomatitis virusDirection-selective retinal ganglion cellsRetinal ganglion cell typesGanglion cell typesRetinal ganglion cellsStomatitis virusCell typesDensity of neuropilTranssynaptic tracerNeurotropic virusesPresynaptic sourceAmacrine cellsSynaptic relationshipsGanglion cellsRetinal circuitryPostsynaptic neuronsSynaptic partnersMouse retinaViral tracersCell type-specific dissectionNeural circuitsNeural circuitryViral spreadVirus
2012
Highly Attenuated Recombinant Vesicular Stomatitis Virus VSV-12′GFP Displays Immunogenic and Oncolytic Activity
van den Pol A, Davis J. Highly Attenuated Recombinant Vesicular Stomatitis Virus VSV-12′GFP Displays Immunogenic and Oncolytic Activity. Journal Of Virology 2012, 87: 1019-1034. PMID: 23135719, PMCID: PMC3554062, DOI: 10.1128/jvi.01106-12.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsGene Expression ProfilingGenes, ReporterGliomaGreen Fluorescent ProteinsHumansMiceMice, SCIDMolecular Sequence DataOncolytic VirusesRNA, ViralSequence Analysis, DNASurvival AnalysisTreatment OutcomeVaccines, AttenuatedVaccines, SyntheticVesiculovirusViral Plaque AssayViral VaccinesConceptsVesicular stomatitis virusGreen fluorescent proteinReporter geneOne-step growth curveVesicular stomatitis virus genomeAttenuated vesicular stomatitis virusCancer cellsHigh-titer antibody responsesInjection of tumorHuman cancer cellsSuppressed tumor growthRNA transcriptsOncolytic virusesIntratumoral injectionSCID micePostnatal daySafety profileFluorescent proteinTumor growthVSV-G/GFPGenesRecombinant virusesStomatitis virusImmune responseAntibody responseA Chimeric Vesiculo/Alphavirus Is an Effective Alphavirus Vaccine
Chattopadhyay A, Wang E, Seymour R, Weaver SC, Rose JK. A Chimeric Vesiculo/Alphavirus Is an Effective Alphavirus Vaccine. Journal Of Virology 2012, 87: 395-402. PMID: 23077320, PMCID: PMC3536361, DOI: 10.1128/jvi.01860-12.Peer-Reviewed Original ResearchConceptsChikungunya virusVesicular stomatitis virusChimeric vesicular stomatitis virusAlphavirus vaccinesCellular immune responsesAlphavirus chikungunya virusMosquito-transmitted alphavirusCHIKV glycoproteinsCHIKV infectionCHIKV vaccineLicensed vaccineSingle doseWorldwide epidemicChikungunya feverImmune responseExperimental vaccinesAlphavirus infectionMultiple recent outbreaksVaccineHigh titersChimeric virusesSerious human diseasesVSV glycoproteinVirusRecent outbreak
2010
A Vesicular Stomatitis Virus-Based Hepatitis B Virus Vaccine Vector Provides Protection against Challenge in a Single Dose
Cobleigh MA, Buonocore L, Uprichard SL, Rose JK, Robek MD. A Vesicular Stomatitis Virus-Based Hepatitis B Virus Vaccine Vector Provides Protection against Challenge in a Single Dose. Journal Of Virology 2010, 84: 7513-7522. PMID: 20504927, PMCID: PMC2897621, DOI: 10.1128/jvi.00200-10.Peer-Reviewed Original ResearchConceptsHepatitis B virusT cell responsesSingle immunizationVaccine vectorVesicular stomatitis virusCD8 T cell responsesCD8 T cell activationSerious worldwide public health problemWorldwide public health problemRecombinant protein immunizationEffective prophylactic vaccineCommon infectious diseasesRecombinant vesicular stomatitis virusSimilar antibody titersPublic health problemRecombinant protein vaccineT cell activationStomatitis virusHBV vaccineLiver diseaseProphylactic vaccinesAntibody titersMultiple dosesProtein immunizationSingle dose
2009
Viral Mutagenesis as a Means for Generating Novel Proteins
Davis J, van den Pol A. Viral Mutagenesis as a Means for Generating Novel Proteins. Journal Of Virology 2009, 84: 1625-1630. PMID: 19906913, PMCID: PMC2812339, DOI: 10.1128/jvi.01747-09.Peer-Reviewed Original ResearchConsequences of host adaptation for performance of vesicular stomatitis virus in novel thermal environments
Alto B, Turner P. Consequences of host adaptation for performance of vesicular stomatitis virus in novel thermal environments. Evolutionary Ecology 2009, 24: 299-315. DOI: 10.1007/s10682-009-9307-3.Peer-Reviewed Original ResearchHost adaptationVesicular stomatitis virusRNA virusesNovel thermal environmentThermal reaction normsStomatitis virusGeneralist traitsHost generalistsFitness traitsNiche specializationGeneralist organismsSpecies biodiversityReaction normsSelective advantageViral genesGeneralistsMultiple hostsViral proteinsSingle hostTraitsExtreme temperaturesWarm environmentNew environmentHostAdaptationAbsence of autophagy results in reactive oxygen species-dependent amplification of RLR signaling
Tal MC, Sasai M, Lee HK, Yordy B, Shadel GS, Iwasaki A. Absence of autophagy results in reactive oxygen species-dependent amplification of RLR signaling. Proceedings Of The National Academy Of Sciences Of The United States Of America 2009, 106: 2770-2775. PMID: 19196953, PMCID: PMC2650341, DOI: 10.1073/pnas.0807694106.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAutophagyAutophagy-Related Protein 5Cells, CulturedDEAD Box Protein 58DEAD-box RNA HelicasesDNA, MitochondrialEnzyme-Linked Immunosorbent AssayFlow CytometryInterferon Type IMacrophagesMiceMicrotubule-Associated ProteinsMitochondriaReactive Oxygen SpeciesReverse Transcriptase Polymerase Chain ReactionSignal TransductionConceptsReactive oxygen speciesDysfunctional mitochondriaInnate antiviral defenseAntiviral defenseKey antiviral cytokinesAbsence of autophagyMitochondrial reactive oxygen speciesHomeostatic regulationRole of autophagyTreatment of cellsIPS-1RLR signalingVesicular stomatitis virusAutophagy resultsRNA virusesWT cellsMitochondriaAutophagyType I IFNStomatitis virusRLRLike receptorsOxygen speciesNeurodegenerative diseasesInflammatory disorders
2008
Single-dose, virus-vectored vaccine protection against Yersinia pestis challenge: CD4+ cells are required at the time of challenge for optimal protection
Chattopadhyay A, Park S, Delmas G, Suresh R, Senina S, Perlin DS, Rose JK. Single-dose, virus-vectored vaccine protection against Yersinia pestis challenge: CD4+ cells are required at the time of challenge for optimal protection. Vaccine 2008, 26: 6329-6337. PMID: 18832004, PMCID: PMC2628553, DOI: 10.1016/j.vaccine.2008.09.031.Peer-Reviewed Original ResearchConceptsTime of challengeVesicular stomatitis virusVaccine protectionAnti-LcrV antibodySingle-dose protectionDepletion of CD4Recombinant vesicular stomatitis virusYersinia pestis challengeCellular immunityAntibody titersSingle doseIgG1 isotypePlague vaccineLcrV proteinOptimal protectionPlague challengeCD4Stomatitis virusCellsCD8IgG2aVaccineMiceDoseTiters
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply